Grufity logoGrufity logo

STOK

7.36USD+0.03(+0.41%)Market Closed

Stoke Therapeutics, Inc.

Market Summary

USD7.36+0.03Market Closed
0.41%

STOK Stock Price

RSI Chart

Valuation

Market Cap

618.5M

Price/Earnings

-6.42

Price/Sales

49.63

Price/Cashflow

-33.66

Price/Sales

Profitability

Return on Equity

-42.95%

Return on Assets

-31.96%

Fundamentals

Revenue

Revenue (TTM)

12.2M

Earnings

Earnings (TTM)

-99.9M

Earnings Y/Y

-15.55%

Earnings Q/Q

-5.92%

Price Action

52 Week Range

26.60
(Low)(High)

Last 7 days

0.4%

Last 30 days

-43.9%

Last 90 days

-51.5%

Trailing 12 Months

-69.1%

Financial Health

Current Ratio

10.46

Investor Care

Shares Dilution (1Y)

7.18%

Diluted EPS (TTM)

-2.59

Peers (Alternatives to Stoke Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
13.24% 45.49%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
13.13% -41.64%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
3.50% 20.88%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
3.66% 57.19%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
9.35% 28.19%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
9.82% 47.16%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
11.31% 51.76%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-3.30% 6.13%
-18.85
63.29
26.15% -23.38%
3.8B
-
48.10% -29.78%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
6.14% -50.33%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-1.03% -49.23%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
27.64% 144.62%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
12.76% -3.22%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
42.27% -60.18%
-1.4
4.57
-43.57% -69.06%
16.0M
-
3.64% -84.06%
-0.46
19.11
-77.61% 5.14%

Financials for Stoke Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q1
Revenue-2.3%121212
Operating Expenses7.1%11110397
  S&GA Expenses4.4%383734
  R&D Expenses8.6%736763
Net Income-3.6%-99.86-96.35-93.66
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-7.9%278301316239254
  Current Assets-8.5%265289306229245
    Cash Equivalents67.4%1136884145149
  Net PPE22.0%76543
Liabilities-4.7%7377762116
  Current Liabilities4.1%2928231712
Shareholder's Equity-9.0%204224240218238
  Retained Earnings-10.6%-271.49-245.38-220.73-196.08-171.63
  Additional Paid-In Capital1.4%477471461414409
Accumulated Depreciation-3----
Shares Outstanding0.1%3939393737
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-40.1%-25.75-18.38-14.28-66.91-61.58
  Share Based Compensation6.4%2220191613
Cashflow From Investing56.2%-56.57-129.10-212.00-76.43-88.31
Cashflow From Financing0.1%4747431108

Risks

What is the probability of a big loss on STOK?

93.4%


Probability that Stoke Therapeutics stock will be more than 20% underwater in next one year

84.6%


Probability that Stoke Therapeutics stock will be more than 30% underwater in next one year.

75.8%


Probability that Stoke Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does STOK drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Stoke Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on STOK

-32.9%


3-Year Cumulative Returns

Which funds bought or sold STOK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
547,000
547,000
0.01%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-4,000
287,000
-%
2022-11-15
ALGERT GLOBAL LLC
NEW
-
1,027,000
1,027,000
0.06%
2022-11-15
JANE STREET GROUP, LLC
NEW
-
222,000
222,000
-%
2022-11-15
ALLIANCEBERNSTEIN L.P.
ADDED
16.03
40,000
353,000
-%
2022-11-15
Balyasny Asset Management LLC
NEW
-
147,000
147,000
-%
2022-11-15
STATE STREET CORP
ADDED
7.69
236,000
5,284,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
19.03
29,811
219,718
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-14
Bank of New York Mellon Corp
-
-
82,000
1,029,000
-%

1–10 of 46

Latest Funds Activity

Are funds buying STOK calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own STOK

Stoke Therapeutics News

Marketscreener.com

Stoke Therapeutics : Presents Data from a Combined Interim Analysis of the Phase 1/2a - Form 8-K.24 hours ago

STOK Fair Value

Recent SEC filings of Stoke Therapeutics

View All Filings
Date Filed Form Type Document
Nov 14, 2022
8-K
Current Report
Nov 14, 2022
10-Q
Quarterly Report

Latest Insider Trading transactions for STOK

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-06-02
Tulipano Stephen J
ACQUIRED
49,996.8
4.48
11,160
CFO
2022-05-25
Kaye Edward M. MD
ACQUIRED
9,000
0.6
15,000
CEO
2022-01-03
Nash Huw M.
ACQUIRED
8,322
2.19
3,800
COO & CBO
2022-01-03
Nash Huw M.
SOLD
-87,666.1
23.07
-3,800
COO & CBO
2021-12-01
Nash Huw M.
ACQUIRED
12,483
2.19
5,700
COO & CBO
2021-12-01
Nash Huw M.
SOLD
-139,330
24.4438
-5,700
COO & CBO
2021-11-03
Nash Huw M.
SOLD
-47,500
25
-1,900
COO & CBO
2021-11-03
Nash Huw M.
ACQUIRED
4,161
2.19
1,900
COO & CBO
2021-11-01
Nash Huw M.
SOLD
-89,456.5
23.5412
-3,800
COO & CBO
2021-11-01
Nash Huw M.
ACQUIRED
8,322
2.19
3,800
COO & CBO

1–10 of 50

Edward M. Kaye
100
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

STOK Income Statement

2022-09-30
Condensed consolidated statements of operations and comprehensive loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue$ 2,905 $ 9,137 
Operating expenses:    
Research and development20,109$ 14,35856,777$ 38,366
General and administrative9,9448,32529,54023,173
Total operating expenses30,05322,68386,31761,539
Loss from operations(27,148)(22,683)(77,180)(61,539)
Other income:    
Interest income (expense), net995441,64384
Other income (expense), net424212598
Total other income1,037861,768182
Net loss$ (26,111)$ (22,597)$ (75,412)$ (61,357)
Net loss per share, basic$ (0.66)$ (0.61)$ (1.95)$ (1.67)
Net loss per share, diluted$ (0.63)$ (0.60)$ (1.29)$ (1.06)
Weighted-average common shares outstanding, basic39,420,31036,759,31938,716,61536,706,647
Weighted-average common shares outstanding, diluted39,258,35836,708,18838,358,93636,675,876
Comprehensive loss:    
Net loss$ (26,111)$ (22,597)$ (75,412)$ (61,357)
Other comprehensive gain (loss):    
Unrealized gain (loss) on marketable securities(427)20(1,535)(22)
Total other comprehensive loss(427)20(1,535)(22)
Comprehensive loss$ (26,538)$ (22,577)$ (76,947)$ (61,379)

STOK Balance Sheet

2022-09-30
Condensed consolidated balance sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 113,396$ 144,895
Marketable securities138,25974,915
Prepaid expenses and other current assets12,5519,159
Deferred financing costs 117
Interest receivable395132
Total current assets264,601229,218
Restricted cash569569
Operating lease right-of-use assets5,2954,939
Property and equipment, net7,1614,139
Total assets277,626238,865
Current liabilities:  
Accounts payable1,9112,385
Accrued and other current liabilities14,04614,754
Deferred revenue - current portion12,838 
Total current liabilities28,79517,139
Deferred revenue - net of current portion41,078 
Other long term liabilities3,6103,949
Total long term liabilities44,6883,949
Total liabilities73,48321,088
Commitments and contingencies (Note 6)
Stockholders’ equity  
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 39,426,440 and 36,902,499 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively44
Additional paid-in capital477,337414,024
Accumulated other comprehensive loss(1,703)(168)
Accumulated deficit(271,495)(196,083)
Total stockholders’ equity204,143217,777
Total liabilities and stockholders’ equity$ 277,626$ 238,865